TY - JOUR
T1 - Activation of KATP channels in pain modulation
T2 - a systematic review of preclinical studies
AU - Beich, Signe Schønning
AU - Kokoti, Lili
AU - Al-Karagholi, Mohammad Al-Mahdi
N1 - Copyright © 2025 Beich, Kokoti and Al-Karagholi.
PY - 2025
Y1 - 2025
N2 - OBJECTIVE: To systematically review the involvement of KATP channel activation in pain modulation in preclinical studies.BACKGROUND: KATP channels are expressed at several levels in the spinal and trigeminal pain pathways, where they seem to modulate nociceptive transmission.METHODS: PubMed and Embase databases were searched until 29 January 2024, using the following search string: [(pain) OR (nociception) OR (antinociception) AND (KATP channel) OR (ATP sensitive potassium channel)]. Non-English and unavailable records, as well as records with non-experimental methodology, were excluded. Inclusion criteria were preclinical studies measuring pain in vivo upon activation of the KATP channel by administering a stimulator or positive modulator. Records were screened based on title and abstract, and those that met the study inclusion criteria were reviewed based on study design, measurements, intervention, and outcomes.RESULTS: The search resulted in 569 records. In total, 126 duplicates were detected. Subsequently, 438 records were screened by title and abstract, resulting in the exclusion of 396. Based on inclusion criteria, 42 studies were included. The main findings of the present systematic review were that KATP channel openers can attenuate induced pain in various animal models and potentiate the effects of analgesics.CONCLUSION: Local, systemic, spinal, and supraspinal activation of KATP channels can attenuate pain and potentiate the efficacy of analgesic drugs. One exception was levcromakalim, as the systemic levcromakalim administration, but not a local application, induced pain. This finding is consistent with those of recent human trials. Future studies should investigate the differences in KATP channel activation between rodents and humans, as well as the differences in activation sites between levcromakalim and other KATP channel openers.
AB - OBJECTIVE: To systematically review the involvement of KATP channel activation in pain modulation in preclinical studies.BACKGROUND: KATP channels are expressed at several levels in the spinal and trigeminal pain pathways, where they seem to modulate nociceptive transmission.METHODS: PubMed and Embase databases were searched until 29 January 2024, using the following search string: [(pain) OR (nociception) OR (antinociception) AND (KATP channel) OR (ATP sensitive potassium channel)]. Non-English and unavailable records, as well as records with non-experimental methodology, were excluded. Inclusion criteria were preclinical studies measuring pain in vivo upon activation of the KATP channel by administering a stimulator or positive modulator. Records were screened based on title and abstract, and those that met the study inclusion criteria were reviewed based on study design, measurements, intervention, and outcomes.RESULTS: The search resulted in 569 records. In total, 126 duplicates were detected. Subsequently, 438 records were screened by title and abstract, resulting in the exclusion of 396. Based on inclusion criteria, 42 studies were included. The main findings of the present systematic review were that KATP channel openers can attenuate induced pain in various animal models and potentiate the effects of analgesics.CONCLUSION: Local, systemic, spinal, and supraspinal activation of KATP channels can attenuate pain and potentiate the efficacy of analgesic drugs. One exception was levcromakalim, as the systemic levcromakalim administration, but not a local application, induced pain. This finding is consistent with those of recent human trials. Future studies should investigate the differences in KATP channel activation between rodents and humans, as well as the differences in activation sites between levcromakalim and other KATP channel openers.
UR - http://www.scopus.com/inward/record.url?scp=85219375173&partnerID=8YFLogxK
U2 - 10.3389/fphys.2025.1444270
DO - 10.3389/fphys.2025.1444270
M3 - Review
C2 - 39981304
SN - 1664-042X
VL - 16
SP - 1444270
JO - Frontiers in Physiology
JF - Frontiers in Physiology
M1 - 1444270
ER -